REPCF (0913693 BC) Beta: 0.0484 (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is 0913693 BC Beta?

0913693 BC REPCF Beta is 0.0484 as of Jul. 21, 2026.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-21), 0913693 BC's Beta is 0.0484.


0913693 BC  (OTCPK:REPCF) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


0913693 BC Beta Related Terms


0913693 BC Beta Historical Data

* Premium members only.

The historical data trend for 0913693 BC's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

0913693 BC Beta Chart

0913693 BC Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.86 1.13 1.09 0.65 0.96

0913693 BC Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.89 0.96 1.23 1.36 1.48

REPCF vs VRTX, REGN, SGEN: Beta Comparison

For the Biotechnology subindustry, 0913693 BC's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


0913693 BC Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 0913693 BC's Beta distribution charts can be found below:

* The bar in red indicates where 0913693 BC's Beta falls into.



0913693 BC Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.0484 mean?
0913693 BC (REPCF) has a Beta of 0.0484 as of Jul. 21, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for 0913693 BC and its competitors.
Is 0913693 BC's Beta too high?
0913693 BC's current Beta is 0.0484.
How does 0913693 BC's Beta compare to VRTX and REGN?
0913693 BC's Beta of 0.0484 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for 0913693 BC and its competitors. 0913693 BC's current Beta is 0.0484. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 0913693 BC stock overvalued right now?
0913693 BC (REPCF) has a current Beta of 0.0484. The current Beta is 0.0484. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For 0913693 BC (REPCF), the current Beta is 0.0484 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

0913693 BC Business Description

Address 570 Granville Street, Suite 900, Vancouver, BC, CAN, V6C 3P1
0913693 BC Ltd is a regenerative medicine company focused on aesthetics and orthopedics. It is a royalty company that holds its primary royalty assets focused on autologous cell therapies that treat functional cellular deficits, including chronic tendon injuries, androgenetic alopecia, and skin aging. The Company is organized into one business unit based on its cell replication technology and has one reportable operating segment. Its product line is RCT-01 Tendon Repair, RCS-01 Skin Rejuvenation, RCH-01 Hair Growth, and DermaPrecise.